Annovis Bio Reports Biomarker Data Showing Buntanetap Reduces Inflammation and Improves Neuronal Health in Alzheimer's Patients

Annovis Bio Inc. has announced new biomarker data from its Phase 2/3 study showing that its experimental drug buntanetap reduces inflammation and strengthens neuronal health in Alzheimer's disease patients. The company reported that buntanetap treatment led to lower levels of key inflammatory biomarkers including IL-5, IL-6, S100A12, IFN-γ, and IGF1R compared to placebo groups. These findings provide important insights into how buntanetap may be working at the molecular level to potentially modify disease progression rather than simply treating symptoms.

The reduction in multiple inflammatory markers is particularly significant given the growing understanding of inflammation's role in Alzheimer's disease progression. The findings also showed reduced neurofilament light chain levels in treated patients, suggesting improved cellular health and potential disease-modifying effects. Neurofilament light chain is a biomarker that indicates neuronal damage, and its reduction suggests buntanetap may be protecting nerve cells from degeneration. These results build on earlier preclinical and clinical data supporting buntanetap's multi-targeted mechanism of action in neurodegenerative diseases.

CEO Maria Maccechini stated that the biomarker findings confirm buntanetap's mechanism and validate previous research results, advancing confidence in the drug's potential to deliver meaningful therapeutic benefits for Alzheimer's patients. The company is developing buntanetap as a therapy for multiple neurodegenerative diseases including both Alzheimer's and Parkinson's disease. By targeting multiple pathways simultaneously, buntanetap represents a novel approach to treating neurodegenerative conditions that typically involve complex biological processes.

The biomarker data comes from Annovis Bio's ongoing clinical development program for buntanetap, which the company is positioning as a potential disease-modifying therapy for Alzheimer's disease. These latest results contribute to the evolving understanding of how therapeutic interventions might effectively address the underlying mechanisms of Alzheimer's disease rather than merely managing symptoms. The findings suggest the drug may be addressing fundamental pathological processes in neurodegeneration, offering hope for more effective treatments for conditions that currently have limited therapeutic options. Additional information about the company's research can be found through their corporate communications at https://ibn.fm/ANVS.